nab-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program. Dickson, M., Ravi, V., Riedel, R. F., Ganjoo, K. N., Van Tine, B., Chugh, R., Cranmer, L. D., Gordon, E., Chen, J., Murphy, M., Schmid, A. N., Desai, N., Palma, N., Kwiatkowski, D. J., Wagner, A. J. LIPPINCOTT WILLIAMS & WILKINS. 2022

View details for Web of Science ID 000863680300415